ANEB Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

$6.27
As of 11/26/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/07/2021
Outstanding shares:  23,344,567
Average volume:  2,885
Market cap:   $155,241,371
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    034569103
ISIN:        US0345691036
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   7.36
PS ratio:   0.00
Return on equity:   -159.89%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy